Juan Lawrence Cabatu, NP
Family · Westchester, ILNPI 1093184582
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $73,350 of the $100,374 with a category attached, or 73.1%. Acadia Pharmaceuticals Inc accounts for 62.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $28,386, 3.1 times the $9,222 reported in 2021. Among family clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $328.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$63K
- Teva Pharmaceuticals USA, Inc.$31K
- Axsome Therapeutics, Inc.$5K
- Genentech USA, Inc.$750
- Neurocrine Biosciences, Inc.$308
- E.r. Squibb & Sons, L.L.C.$226
- plus $603 from 5 others
What the payments were for
- Consulting fees$2,4432%
- Speaking & faculty fees$73,35073%
- Travel & lodging$14,70515%
- Food & beverage$9,64510%
- Education$2310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 178 | $63,151 |
| Teva Pharmaceuticals USA, Inc. | 87 | $30,634 |
| Axsome Therapeutics, Inc. | 6 | $4,702 |
| Genentech USA, Inc. | 1 | $750 |
| Neurocrine Biosciences, Inc. | 11 | $308 |
| E.r. Squibb & Sons, L.L.C. | 8 | $226 |
| Johnson & Johnson | 2 | $221 |
| Otsuka America Pharmaceutical, Inc. | 2 | $136 |
| Alpha Cognition USA, Inc. | 5 | $132 |
| Avanir Pharmaceuticals, Inc. | 5 | $97 |
| Alkermes, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$60,462
- Austedo XR$27,760
- AUSTEDO$1,481
- SPRAVATO$127
- COBENFY$122
- ABILIFY MAINTENA$118
- INGREZZA$116
How this compares
$100,374 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 203 | $930,039 |
| NuplazidPimavanserin Tartrate | 150 | $276,313 |
| IngrezzaValbenazine Tosylate | 25 | $198,817 |
| RexultiBrexpiprazole | 291 | $198,803 |
| Abilify MaintenaAripiprazole | 12 | $30,146 |
| Risperdal ConstaRisperidone Microspheres | 12 | $29,518 |
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $17,051 |
| Divalproex Sodium | 638 | $15,253 |
| Clozapine OdtClozapine | 48 | $12,579 |
| Memantine Hcl ErMemantine Hcl | 197 | $12,039 |
| Quetiapine Fumarate | 615 | $7,543 |
| Clozapine | 86 | $6,566 |
| Aripiprazole | 149 | $5,630 |
| Memantine Hcl | 344 | $5,532 |
| Trazodone Hcl | 849 | $5,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $30,634 | $930,039203 claims |
| Acadia Pharmaceuticals IncNuplazid | $63,151 | $276,313150 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $136 | $228,949303 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $308 | $198,81725 claims |
| Johnson & JohnsonRisperdal Consta | $221 | $29,51812 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $97 | $17,05126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.
Other family in Westchester
- Ruth CarricoChicago$578K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Amy BrownellElk Grove Village$202K
- Brittony CroasdellChicago$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.